Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy.
作者信息
Roy Swarnava, Rai Parul, Eiymo Mwa Mpollo Marthe-Sandrine, Chang Kyung-Hee, Rizvi Tilat, Shanmukhappa Shiva Kumar, VandenHeuvel Katherine, Aronow Bruce, Inagami Tadashi, Cancelas Jose A, Malik Punam
机构信息
Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Research Foundation, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229.
Division of Hematology, Cancer and Blood Diseases Institute, Hoxworth Blood Center, Cincinnati, Ohio, 45267.
出版信息
Am J Hematol. 2018 Jul;93(7):E177-E181. doi: 10.1002/ajh.25118. Epub 2018 May 15.
Abstract
摘要
相似文献
1
Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy.血管紧张素受体信号传导在镰状细胞贫血中对尿液浓缩能力具有肾保护作用，但会导致镰状细胞性肾小球病。
Am J Hematol. 2018 Jul;93(7):E177-E181. doi: 10.1002/ajh.25118. Epub 2018 May 15.
2
The role of prostaglandins and renin in sickle-cell nephropathy. A hypothesis.前列腺素和肾素在镰状细胞肾病中的作用。一种假说。
Neth J Med. 1978;21(2):67-72.
3
Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia.氯沙坦治疗可降低镰状细胞贫血患者的蛋白尿，同时维持肾小球滤过和选择性通透功能稳定。
Blood Cells Mol Dis. 2018 Mar;69:65-70. doi: 10.1016/j.bcmd.2017.09.006. Epub 2017 Sep 21.
4
[Spectrum of renal manifestations in sickle cell disease].[镰状细胞病的肾脏表现谱]
Nephrol Ther. 2014 Feb;10(1):10-6. doi: 10.1016/j.nephro.2013.07.366. Epub 2013 Oct 7.
5
Nature of concentrating defect in sickle-cell nephropathy. Microradioangiographic studies.镰状细胞肾病中浓缩功能缺陷的本质。微血管造影研究。
Lancet. 1970 Feb 28;1(7644):450-2. doi: 10.1016/s0140-6736(70)90836-6.
6
Sickle-cell nephropathy.镰状细胞肾病
Ann Intern Med. 1970 Sep;73(3):488-9. doi: 10.7326/0003-4819-73-3-488.
7
Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.血管紧张素转换酶抑制与血管紧张素II受体阻断在预防实验性自身免疫性心肌炎中的比较
Int J Cardiol. 2008 Mar 28;125(1):85-93. doi: 10.1016/j.ijcard.2007.04.062. Epub 2007 Jun 22.
8
The kidney in sickle cell disease and multiple myeloma.镰状细胞病和多发性骨髓瘤中的肾脏。
Perspect Nephrol Hypertens. 1976;3:77-93.
9
Chronic losartan treatment decreases angiotensin II-mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats.长期氯沙坦治疗可降低血管紧张素II介导的去甲肾上腺素在自发性高血压大鼠尾动脉中的释放促进作用。
Life Sci. 2000 Nov 17;67(26):3153-62. doi: 10.1016/s0024-3205(00)00900-0.
引用本文的文献
1
End Organ Affection in Sickle Cell Disease.镰状细胞病的靶器官损害。
Cells. 2024 May 29;13(11):934. doi: 10.3390/cells13110934.
2
The Angiotensin AT Receptor: From a Binding Site to a Novel Therapeutic Target.血管紧张素 AT 受体：从结合位点到新的治疗靶点。
Pharmacol Rev. 2022 Oct;74(4):1051-1135. doi: 10.1124/pharmrev.120.000281.
3
ATR1 Angiotensin II Receptor Reduces Hemoglobin S Polymerization, Phosphatidylserine Exposure, and Increases Deformability of Sickle Cell Disease Erythrocytes.ATR1 血管紧张素 II 受体可减少镰状细胞病红细胞中血红蛋白 S 的聚合、磷脂酰丝氨酸暴露，并增加其变形性。
Cell Biochem Biophys. 2022 Dec;80(4):711-721. doi: 10.1007/s12013-022-01096-y. Epub 2022 Sep 29.
4
Improvement of hemolytic anemia with GBT1118 is renoprotective in transgenic sickle mice.GBT1118 可改善遗传性血溶性贫血，并对转基因镰状细胞小鼠具有肾保护作用。
Blood Adv. 2022 Aug 9;6(15):4403-4407. doi: 10.1182/bloodadvances.2022007809.
5
The nephropathy of sickle cell trait and sickle cell disease.镰状细胞性状和镰状细胞病的肾病
Nat Rev Nephrol. 2022 Jun;18(6):361-377. doi: 10.1038/s41581-022-00540-9. Epub 2022 Feb 21.
6
Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.镰状细胞病患者的血压降低与血管紧张素转换酶 (ACE) 活性降低有关，而不受 ACE 抑制的调节。
PLoS One. 2022 Feb 3;17(2):e0263424. doi: 10.1371/journal.pone.0263424. eCollection 2022.
7
Sickle cell nephropathy: A review of novel biomarkers and their potential roles in early detection of renal involvement.镰状细胞肾病：新型生物标志物及其在肾脏受累早期检测中的潜在作用综述
World J Clin Pediatr. 2022 Jan 9;11(1):14-26. doi: 10.5409/wjcp.v11.i1.14.
8
Levels of angiotensin-converting enzyme 1 and 2 in serum and urine of children with Sickle Cell Disease.血清和尿液中血管紧张素转换酶 1 和 2 在镰状细胞病患儿中的水平。
J Bras Nefrol. 2021 Jul-Sep;43(3):303-310. doi: 10.1590/2175-8239-JBN-2020-0174.
9
Cardiac pathophysiology in sickle cell disease.镰状细胞病的心脏病理生理学
J Thromb Thrombolysis. 2021 Jul;52(1):248-259. doi: 10.1007/s11239-021-02414-6. Epub 2021 Mar 7.
10
Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.镰状细胞贫血患者白蛋白尿的进展：一项多中心、纵向研究。
Blood Adv. 2020 Apr 14;4(7):1501-1511. doi: 10.1182/bloodadvances.2019001378.
本文引用的文献
1
AT2 receptors in cardiovascular and renal diseases.心血管和肾脏疾病中的 AT2 受体。
Pharmacol Res. 2017 Nov;125(Pt A):39-47. doi: 10.1016/j.phrs.2017.07.008. Epub 2017 Jul 8.
2
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.血管紧张素转换酶（ACE）抑制剂用于镰状细胞病患者的蛋白尿和微量白蛋白尿。
Cochrane Database Syst Rev. 2015 Jun 4;2015(6):CD009191. doi: 10.1002/14651858.CD009191.pub3.
3
Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT₂R and cytoskeletal dysregulation.血管病变相关的高血管紧张素血症通过内皮细胞AT₂R和细胞骨架失调动员造血干细胞/祖细胞。
Nat Commun. 2015 Jan 9;6:5914. doi: 10.1038/ncomms6914.
4
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.镰状细胞病的管理：专家小组成员 2014 年循证报告的总结。
JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517.
5
TGF-β/Smad signaling in kidney disease.TGF-β/Smad 信号通路在肾脏疾病中的作用。
Semin Nephrol. 2012 May;32(3):236-43. doi: 10.1016/j.semnephrol.2012.04.002.
6
AT1 receptors in the collecting duct directly modulate the concentration of urine.集合管中的 AT1 受体直接调节尿液浓度。
J Am Soc Nephrol. 2011 Dec;22(12):2237-46. doi: 10.1681/ASN.2010101095. Epub 2011 Nov 3.
Zotero 插件